Abstract:Metabolic diseases such as nonalcoholic fatty liver disease (NAFLD) are rising in incidence and are an increasingly common cause of cirrhosis and hepatocellular carcinoma (HCC). The gut microbiome is closely connected to the liver via the portal vein, and has recently been identified as a predictor of liver disease state. Studies in NAFLD, cirrhosis and HCC have identified certain microbial signatures associated with these diseases, with the disease-associated microbiome changes collectively referred to as dysbiosis. The pathophysiologic underpinnings of these observations are an area of ongoing investigation, with current evidence demonstrating that the gut microbiome can influence liver disease and carcinogenesis via effects on intestinal permeability (leaky gut) and activation of the innate immune system. In the innate immune system, pathogen recognition receptors (Toll like receptors) on resident liver cells and macrophages cause liver inflammation, fibrosis, hepatocyte proliferation and reduced antitumor immunity, leading to chronic liver disease and carcinogenesis. Dysbiosis-associated changes include increase in secondary bile acids and reduced expression of FXR (nuclear receptor), which have also been associated with deleterious effects on lipid and carbohydrate metabolism associated with progressive liver disease. Longitudinal experimental and clinical studies are needed in different populations to examine these questions further. The role of therapeutics that modulate the microbiome is an emerging field with experimental studies showing the potential of diet, probiotics, fecal microbiota transplantation and prebiotics in improving liver disease in experimental models. Clinical studies are ongoing with preliminary evidence showing improvement in liver enzymes and steatosis. The microbial profile is different in responders to cancer immunotherapy including liver cancer, but whether or not manipulation of the microbiome can be utilized to affect response is being investigated.

The Microbiome and Liver Cancer

Modulation of Gut Microbiota by Probiotics to Improve the Efficacy of Immunotherapy in Hepatocellular Carcinoma

The microbiome and hepatobiliary-pancreatic cancers

The Gut Microbiome as a Biomarker and Therapeutic Target in Hepatocellular Carcinoma

Unveiling the complex relationship between gut microbiota and liver cancer: opportunities for novel therapeutic interventions

Gut microbiota: impacts on gastrointestinal cancer immunotherapy

Gut Microbiome and Cancer: From Cancer Development to Therapeutics with a Special Focus on Hepatocellular Carcinoma

Utilizing Gut Microbiota to Improve Hepatobiliary Tumor Treatments: Recent Advances

Molecular Immune Mechanism of Intestinal Microbiota and Their Metabolites in the Occurrence and Development of Liver Cancer

Gut microbiota and immune system in liver cancer: Promising therapeutic implication from development to treatment

Potential tactics with certain gut microbiota for the treatment of unresectable hepatocellular carcinoma

Gut microbiome in non-alcoholic fatty liver disease associated hepatocellular carcinoma: Current knowledge and potential for therapeutics

Gut Microbiota Modulation: A Viable Strategy to Address Medical Needs in Hepatocellular Carcinoma and Liver Transplantation

The gut microbiome modulate response to immunotherapy in cancer

Clinical Aspects of Gut Microbiota in Hepatocellular Carcinoma Management

Gut microbiome in gastrointestinal cancer: a friend or foe?

Gut‐liver axis‐mediated mechanism of liver cancer: A special focus on the role of gut microbiota

The Gut Microbiome and Hepatocellular Carcinoma: Implications for Early Diagnostic Biomarkers and Novel Therapies

The Gut Microbiome Controls Liver Tumors via the Vagus Nerve

Role of Gut Microbiota in Hepatocarcinogenesis

Gut microbiome alteration as a diagnostic tool and associated with inflammatory response marker in primary liver cancer